Floatz logo

EF-5

Adult Ependymoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Adult Ependymoma cohort.

Asset / SponsorPhaseRating
Nivolumab
University of Florida
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Cyclophosphamide
Theodore S. Johnson
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Indoximod
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →